BioCentury | Jan 23, 2019
Distillery Techniques

Disease models

TECHNOLOGY: 3-D models A 3-D human tissue model that mimics beating adult myocardium could help assess the effects of heart disease therapies on myocardial contractility. Generation and use of the biomimetic model involves five steps:...
BioCentury | Jun 29, 2018
Tools & Techniques

QT replacement plan

FDA has completed validation of a preclinical assay system that could replace clinical QT testing, a move it hopes will lower development costs and reduce false alarms of arrhythmia risk. The question for drug developers...
BioCentury | Jun 6, 2016
Company News

Tetragenetics, Theranyx deal

The companies partnered to discover and develop therapeutic mAbs against Nav1.6 ( PN4 ; SCN8A ), potassium channel Kv10.1 (KCNH1) and other undisclosed ion channel targets. The partners said they will focus on pain and cancer...
BioCentury | Oct 1, 2015
Distillery Therapeutics

Therapeutics: Potassium channel Kv10.2 (KCNH5; EAG2)

Cancer INDICATION: Brain cancer; cancer Mouse and patient sample studies suggest inhibiting KCNH5 could help treat metastatic medulloblastoma. In eight out of 10 patients with group 3 subtype medulloblastoma, levels of KCNH5 were higher in...
BioCentury | Sep 21, 2015
Clinical News

Vanoxerine: Phase III started

Laguna began the double-blind, placebo-controlled, international Phase III RESTORE SR trial to evaluate a single dose of 400 mg oral vanoxerine in about 600 patients. Laguna Pharmaceuticals Inc. , La Jolla, Calif. Product: Vanoxerine ( GBR-12909 ) Business:...
BioCentury | May 7, 2015
Distillery Techniques

Techniques: Mutations in potassium channel Kv10.1 (KCNH1) and vacuolar H+ ATPase B2 (ATP6V1B2) as diagnostic markers of Zimmermann-Laband syndrome (ZLS)

Biomarkers KCNH1 ATP6V1B2 potassium channel Kv10.1 (KCNH1) University Medical Center Hamburg-Eppendorf BC Staff...
BioCentury | Feb 23, 2015
Finance

An acute arrhythmia alternative

Laguna Pharmaceuticals Inc. plans to use a $30 million series B round to conduct a confirmatory Phase III trial of vanoxerine for acute treatment of atrial fibrillation and atrial flutter. The company is initially targeting...
BioCentury | Feb 18, 2015
Financial News

Laguna raises $30M in B round

Laguna Pharmaceuticals Inc. (La Jolla, Calif.) raised $30 million in a series B round led by new investors Versant Ventures and Frazier Healthcare. New investor BioMed Ventures and existing investor Sante Ventures also participated. Formerly...
BioCentury | Jul 24, 2014
Cover Story

It is an RNA world

RNA-based molecules have redefined the universe of tractable targets by putting virtually anything that is gene encoded within reach of a disease-modifying agent. This redefinition has launched RNA as the biotech industry's third drug modality....
BioCentury | Feb 13, 2014
Tools & Techniques

Micromanaging the microenvironment

A Massachusetts team has designed an in vivo shRNA screen to discover immunosuppressive tumor targets that can be blocked to improve the efficacy of T cell immunotherapies. 1 The screening system shows that current checkpoint...
Items per page:
1 - 10 of 23